FibroBiologics Stock Quote FBLG - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

2.22

Bid

2.17

Ask

2.30

Volume

138,933

2.01 Day's Range 2.2798

1.0779 52 Week Range 55.00

Market Cap

76.943M

Previous Close

2.27

Open

2.2798

Last Trade

6741

2.22

Last Trade Time

Financial Volume

$ 296,217

VWAP

2.1321

Average Volume (3m)

210,331

Shares Outstanding

34,659,125

Dividend Yield

PE Ratio

-4.04

Earnings Per Share (EPS)

-0.55

Revenue

Net Profit

-19.06M

FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to... FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.fibrobiologics.com

Headquarters

Wilmington, Delaware, USA

Founded

FibroBiologics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FBLG. The last closing price for FibroBiologics was $2.27. Over the last year, FibroBiologics shares have traded in a share price range of $ 1.0779 to $ 55.00.

FibroBiologics currently has 34,659,125 shares outstanding. The market capitalization of FibroBiologics is $78.68 million. FibroBiologics has a price to earnings ratio (PE ratio) of -4.04.

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of...

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on...

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development...

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.12	-5.12820512821	2.34	2.55	2.22	101882	2.35712051	CS
4	-0.61	-21.554770318	2.83	2.98	2.15	140164	2.48296566	CS
12	-0.97	-30.407523511	3.19	3.89	2.15	210331	2.95676272	CS
26	-5.35	-70.6737120211	7.57	8.1747	1.0779	331351	3.42151095	CS
52	-27.78	-92.6	30	55	1.0779	245243	5.13176161	CS
156	-27.78	-92.6	30	55	1.0779	245243	5.13176161	CS
260	-27.78	-92.6	30	55	1.0779	245243	5.13176161	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WKEYWISeKey International Holdings AG	$ 7.84 (139.02%)	75.5M
IPHAInnate Pharma SA	$ 3.00 (93.55%)	13.59M
AVLDirexion Daily AVGO Bull 2X Shares	$ 33.67 (48.92%)	642.41k
LOOPLoop Industries Inc	$ 1.8092 (47.09%)	82.11M
AVGXDefiance Daily Target 2X Long AVGO ETF	$ 31.49 (46.67%)	3.42M
RPTXRepare Therapeutics Inc	$ 1.765 (-55.54%)	4.59M
INOInovio Pharmaceuticals Inc New	$ 2.31 (-38.56%)	9.59M
XXII22nd Century Group Inc	$ 0.048 (-34.69%)	41.72M
FLGCFlora Growth Corporation	$ 1.30 (-34.34%)	4.01M
WTOUTime Limited	$ 0.281 (-32.74%)	3.79M
NVDANVIDIA Corporation	$ 134.25 (-2.25%)	228.17M
SOUNSoundHound AI Inc	$ 16.905 (23.66%)	158.74M
TRUGTruGolf Holdings Inc	$ 0.6794 (30.93%)	138.19M
RGTIRigetti Computing Inc	$ 7.155 (19.85%)	122.67M
AVGOBroadcom Inc	$ 224.80 (24.43%)	117.74M